{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:08:35Z","timestamp":1795172915211,"version":"4.10.3"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has highlighted the vulnerability of a globally connected population to zoonotic viruses. The FDA-approved coronavirus antiviral Paxlovid targets the essential SARS-CoV-2 main protease, Mpro. Whilst effective in the acute phase of a COVID infection, Paxlovid cannot be used by all patients, can lead to viral recurrence, and does not protect against post-acute sequelae of COVID-19 (PASC), commonly known as long COVID, an emerging significant health burden that remains poorly understood and untreated. Alternative antivirals that are addressing broader patient needs are urgently required. We here report our drug discovery efforts to target PLpro, a further essential coronaviral protease, for which we report a novel chemical scaffold that targets SARS-CoV-2 PLpro with low nanomolar activity, and which exhibits activity against PLpro of other pathogenic coronaviruses. Our lead compound shows excellent in vivo efficacy in a mouse model of severe acute disease. Importantly, our mouse model recapitulates long-term pathologies matching closely those seen in PASC patients. Our lead compound offers protection against a range of PASC symptoms in this model, prevents lung pathology and reduces brain dysfunction. This provides proof-of-principle that PLpro inhibition may have clinical relevance for PASC prevention and treatment going forward.<\/jats:p>","DOI":"10.1038\/s41467-025-57905-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:08:09Z","timestamp":1743786489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-9833","authenticated-orcid":false,"given":"Stefanie","family":"M. Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-0900","authenticated-orcid":false,"given":"Dale J.","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-7392","authenticated-orcid":false,"given":"Shane M.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9850-4233","authenticated-orcid":false,"given":"Nathan W.","family":"Kuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-9710","authenticated-orcid":false,"given":"Bernadine G. C.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-9951","authenticated-orcid":false,"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-0182","authenticated-orcid":false,"given":"Richard W.","family":"Birkinshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-8037","authenticated-orcid":false,"given":"Reet","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-5359","authenticated-orcid":false,"given":"Rohan","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Khakham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Blackmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-4975","authenticated-orcid":false,"given":"Liana","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle","family":"Dayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-4212","authenticated-orcid":false,"given":"Jan","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus T.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kael","family":"Schoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Maluenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0775-3801","authenticated-orcid":false,"given":"Elizabeth A.","family":"Kleeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody C.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-3037","authenticated-orcid":false,"given":"Gregor","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasiram","family":"Katneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Klemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ueli","family":"Nachbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha Rose","family":"Georgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-496X","authenticated-orcid":false,"given":"Peter E.","family":"Czabotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-8922","authenticated-orcid":false,"given":"Anthony J.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Putoczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-6894","authenticated-orcid":false,"given":"Bernhard C.","family":"Lechtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-5841","authenticated-orcid":false,"given":"Melissa J.","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-8676","authenticated-orcid":false,"given":"Jeffrey P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-4218","authenticated-orcid":false,"given":"Kym N.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-8147","authenticated-orcid":false,"given":"Guillaume","family":"Lessene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-3021","authenticated-orcid":false,"given":"Marcel","family":"Doerflinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8092-4320","authenticated-orcid":false,"given":"David","family":"Komander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"57905_CR1","unstructured":"data.who.int, W. H. O. 2023. WHO Coronavirus (COVID-19) dashboard. https:\/\/data.who.int\/dashboards\/covid19."},{"key":"57905_CR2","doi-asserted-by":"publisher","first-page":"e2282","DOI":"10.1002\/rmv.2282","volume":"32","author":"MM Kesheh","year":"2022","unstructured":"Kesheh, M. M., Hosseini, P., Soltani, S. & Zandi, M. An overview on the seven pathogenic human coronaviruses. Rev. Med. Virol. 32, e2282 (2022).","journal-title":"Rev. Med. Virol."},{"key":"57905_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","volume":"589","author":"P Ball","year":"2021","unstructured":"Ball, P. The lightning-fast quest for COVID vaccines \u2014 and what it means for other diseases. Nature 589, 16\u201318 (2021).","journal-title":"Nature"},{"key":"57905_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41564-023-01356-4","volume":"8","author":"SS Toussi","year":"2023","unstructured":"Toussi, S. S., Hammond, J. L., Gerstenberger, B. S. & Anderson, A. S. Therapeutics for COVID-19. Nat. Microbiol. 8, 771\u2013786 (2023).","journal-title":"Nat. Microbiol."},{"key":"57905_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(22)01214-4","volume":"400","author":"AV Ballering","year":"2022","unstructured":"Ballering, A. V., van Zon, S. K. R., Olde Hartman, T. C. & Rosmalen JGM; Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 400, 452\u2013461 (2022).","journal-title":"Lancet"},{"key":"57905_CR6","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-024-02987-8","volume":"30","author":"M Cai","year":"2024","unstructured":"Cai, M., Xie, Y., Topol, E. J. & Al-Aly, Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat. Med. 30, 1564\u20131573 (2024).","journal-title":"Nat. Med."},{"key":"57905_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/jama.2020.19759","volume":"324","author":"DM Cutler","year":"2020","unstructured":"Cutler, D. M. & Summers, L. H. The COVID-19 Pandemic and the $16 Trillion Virus. JAMA 324, 1495\u20131496 (2020).","journal-title":"JAMA"},{"key":"57905_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"57905_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman, R. T. et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 6, 672\u2013683 (2020).","journal-title":"ACS Cent. Sci."},{"key":"57905_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"57905_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & Clercq, E. D. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"57905_CR12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"57905_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/mol.114.094862","volume":"86","author":"BM Rock","year":"2014","unstructured":"Rock, B. M., Hengel, S. M., Rock, D. A., Wienkers, L. C. & Kunze, K. L. Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4. Mol. Pharmacol. 86, 665\u2013674 (2014).","journal-title":"Mol. Pharmacol."},{"key":"57905_CR14","doi-asserted-by":"publisher","unstructured":"Verma, A. K. et al. Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations. bioRxiv 2024.06.02.596989 https:\/\/doi.org\/10.1101\/2024.06.02.596989 (2024).","DOI":"10.1101\/2024.06.02.596989"},{"key":"57905_CR15","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"57905_CR16","doi-asserted-by":"publisher","unstructured":"Allerton, C. M. N. et al. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02469 (2024).","DOI":"10.1021\/acs.jmedchem.3c02469"},{"key":"57905_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662 (2020).","journal-title":"Nature"},{"key":"57905_CR18","doi-asserted-by":"publisher","first-page":"e106275","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm, T. et al. Mechanism and inhibition of the papain\u2010like protease, PLpro, of SARS\u2010CoV\u20102. Embo J 39, e106275 (2020).","journal-title":"Embo J"},{"key":"57905_CR19","doi-asserted-by":"publisher","first-page":"e1004113","DOI":"10.1371\/journal.ppat.1004113","volume":"10","author":"K Ratia","year":"2014","unstructured":"Ratia, K., Kilianski, A., Baez-Santos, Y. M., Baker, S. C. & Mesecar, A. Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease. PLoS Pathog. 10, e1004113 (2014).","journal-title":"PLoS Pathog."},{"key":"57905_CR20","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia, K. et al. A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA 105, 16119\u201316124 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57905_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.adm9724","volume":"383","author":"B Tan","year":"2024","unstructured":"Tan, B. et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434\u20131440 (2024).","journal-title":"Science"},{"key":"57905_CR22","doi-asserted-by":"publisher","first-page":"eado4288","DOI":"10.1126\/sciadv.ado4288","volume":"10","author":"MR Garnsey","year":"2024","unstructured":"Garnsey, M. R. et al. Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model. Sci. Adv. 10, eado4288 (2024).","journal-title":"Sci. Adv."},{"key":"57905_CR23","doi-asserted-by":"publisher","unstructured":"Lu, Y. et al. Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19. bioRxiv 2024.04.03.587743 https:\/\/doi.org\/10.1101\/2024.04.03.587743 (2024).","DOI":"10.1101\/2024.04.03.587743"},{"key":"57905_CR24","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1016\/j.apsb.2024.04.011","volume":"14","author":"M Zheng","year":"2024","unstructured":"Zheng, M. et al. Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2. Acta Pharm. Sin. B 14, 3286\u20133290 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"57905_CR25","doi-asserted-by":"publisher","first-page":"e33179","DOI":"10.1016\/j.heliyon.2024.e33179","volume":"10","author":"Y Li","year":"2024","unstructured":"Li, Y., Lu, S.-M., Wang, J.-L., Yao, H.-P. & Liang, L.-G. Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19. Heliyon 10, e33179 (2024).","journal-title":"Heliyon"},{"key":"57905_CR26","doi-asserted-by":"publisher","first-page":"876212","DOI":"10.3389\/fchem.2022.876212","volume":"10","author":"DJ Calleja","year":"2022","unstructured":"Calleja, D. J., Lessene, G. & Komander, D. Inhibitors of SARS-CoV-2 PLpro. Front Chem 10, 876212 (2022).","journal-title":"Front Chem"},{"key":"57905_CR27","doi-asserted-by":"publisher","first-page":"861209","DOI":"10.3389\/fchem.2022.861209","volume":"10","author":"DJ Calleja","year":"2022","unstructured":"Calleja, D. J. et al. Insights into drug repurposing, as well as specificity and compound properties of piperidine-based sars-cov-2 plpro inhibitors. Front Chem 10, 861209 (2022).","journal-title":"Front Chem"},{"key":"57905_CR28","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1021\/cb500917m","volume":"10","author":"H Lee","year":"2015","unstructured":"Lee, H. et al. Inhibitor recognition specificity of mers-cov papain-like protease may differ from that of SARS-CoV. ACS Chem. Biol. 10, 1456\u20131465 (2015).","journal-title":"ACS Chem. Biol."},{"key":"57905_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37254-w","volume":"14","author":"BC Sanders","year":"2023","unstructured":"Sanders, B. C. et al. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nat. Commun. 14, 1733 (2023).","journal-title":"Nat. Commun."},{"key":"57905_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50566-9","volume":"15","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape. Nat. Commun. 15, 6219 (2024).","journal-title":"Nat. Commun."},{"key":"57905_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12985-022-01802-5","volume":"19","author":"L Mautner","year":"2022","unstructured":"Mautner, L. et al. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virol. J. 19, 76 (2022).","journal-title":"Virol. J."},{"key":"57905_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., Kleine-Weber, H. & P\u00f6hlmann, S. A multibasic cleavage site in the spike protein of sars-cov-2 is essential for infection of human lung cells. Mol. Cell 78, 779\u2013784.e5 (2020).","journal-title":"Mol. Cell"},{"key":"57905_CR33","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.antiviral.2022.105429","volume":"208","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study. Antivir. Res. 208, 105429 (2022).","journal-title":"Antivir. Res."},{"key":"57905_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21060-3","volume":"12","author":"J Osipiuk","year":"2021","unstructured":"Osipiuk, J. et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 12, 743 (2021).","journal-title":"Nat. Commun."},{"key":"57905_CR35","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","volume":"65","author":"Z Shen","year":"2022","unstructured":"Shen, Z. et al. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 65, 2940\u20132955 (2022).","journal-title":"J. Med. Chem."},{"key":"57905_CR36","doi-asserted-by":"publisher","first-page":"eade1985","DOI":"10.1126\/scisignal.ade1985","volume":"16","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression. Sci Signal 16, eade1985 (2023).","journal-title":"Sci Signal"},{"key":"57905_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"57905_CR38","doi-asserted-by":"publisher","first-page":"e2301689120","DOI":"10.1073\/pnas.2301689120","volume":"120","author":"SM Bader","year":"2023","unstructured":"Bader, S. M. et al. SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates. Proc. Natl. Acad. Sci. 120, e2301689120 (2023).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"57905_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06471-6","volume":"15","author":"SM Bader","year":"2024","unstructured":"Bader, S. M. et al. Necroptosis does not drive disease pathogenesis in a mouse infective model of SARS-CoV-2 in vivo. Cell Death Dis. 15, 100 (2024).","journal-title":"Cell Death Dis."},{"key":"57905_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"57905_CR41","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1182\/bloodadvances.2020003918","volume":"5","author":"J Courjon","year":"2021","unstructured":"Courjon, J. et al. Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity. Blood Adv. 5, 1523\u20131534 (2021).","journal-title":"Blood Adv."},{"key":"57905_CR42","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3389\/fimmu.2020.01580","volume":"11","author":"DF van den Berg","year":"2020","unstructured":"van den Berg, D. F. & Te Velde, A. A. Severe COVID-19: NLRP3 inflammasome dysregulated. Front. Immunol. 11, 1580 (2020).","journal-title":"Front. Immunol."},{"key":"57905_CR43","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.xcrm.2022.100663","volume":"3","author":"C Schulthei\u00df","year":"2022","unstructured":"Schulthei\u00df, C. et al. The IL-1\u03b2, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 3, 100663 (2022).","journal-title":"Cell Rep. Med."},{"key":"57905_CR44","doi-asserted-by":"publisher","first-page":"eabo5070","DOI":"10.1126\/scitranslmed.abo5070","volume":"14","author":"KH DinnonIII","year":"2022","unstructured":"DinnonIII, K. H. et al. SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Sci. Transl. Med. 14, eabo5070 (2022).","journal-title":"Sci. Transl. Med."},{"key":"57905_CR45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41586-024-07926-8","volume":"634","author":"H Narasimhan","year":"2024","unstructured":"Narasimhan, H. et al. An aberrant immune\u2013epithelial progenitor niche drives viral lung sequelae. Nature 634, 961\u2013969 (2024).","journal-title":"Nature"},{"key":"57905_CR46","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41590-024-01868-z","volume":"25","author":"A Vanderheiden","year":"2024","unstructured":"Vanderheiden, A. et al. Vaccination reduces central nervous system IL-1\u03b2 and memory deficits after COVID-19 in mice. Nat. Immunol. 25, 1158\u20131171 (2024).","journal-title":"Nat. Immunol."},{"key":"57905_CR47","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085.e12 (2020).","journal-title":"Cell"},{"key":"57905_CR48","doi-asserted-by":"publisher","first-page":"eabk1741","DOI":"10.1126\/sciimmunol.abk1741","volume":"6","author":"IS Cheon","year":"2021","unstructured":"Cheon, I. S. et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci. Immunol. 6, eabk1741 (2021).","journal-title":"Sci. Immunol."},{"key":"57905_CR49","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s10554-021-02353-6","volume":"37","author":"S Ghidini","year":"2021","unstructured":"Ghidini, S. et al. Echocardiographic assessment of the right ventricle in COVID-19: a systematic review. Int. J. Cardiovasc. Imaging 37, 3499\u20133512 (2021).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"57905_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36223-7","volume":"14","author":"E Xu","year":"2023","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Long-term gastrointestinal outcomes of COVID-19. Nat. Commun. 14, 983 (2023).","journal-title":"Nat. Commun."},{"key":"57905_CR51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/biomedicines11051407","volume":"11","author":"AS Babkina","year":"2023","unstructured":"Babkina, A. S. et al. Morphologic findings in the cerebral cortex in covid-19: association of microglial changes with clinical and demographic variables. Biomedicines 11, 1407 (2023).","journal-title":"Biomedicines"},{"key":"57905_CR52","doi-asserted-by":"publisher","unstructured":"Gressett, T. E. et al. Mouse Adapted SARS-CoV-2 Model Induces \u201cLong-COVID\u201d Neuropathology in BALB\/c Mice. bioRxiv 2023.03.18.533204 https:\/\/doi.org\/10.1101\/2023.03.18.533204 (2023).","DOI":"10.1101\/2023.03.18.533204"},{"key":"57905_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.immunol.021908.132528","volume":"27","author":"RM Ransohoff","year":"2009","unstructured":"Ransohoff, R. M. & Perry, V. H. Microglial Physiology: Unique Stimuli, Specialized Responses. Annu. Rev. Immunol. 27, 119\u2013145 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"57905_CR54","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140\u2013145 (2021).","journal-title":"Nature"},{"key":"57905_CR55","doi-asserted-by":"publisher","unstructured":"Lueptow, L. M. Novel Object Recognition Test for the Investigation of Learning and Memory in Mice. J. Vis. Exp. https:\/\/doi.org\/10.3791\/55718 (2017).","DOI":"10.3791\/55718"},{"key":"57905_CR56","doi-asserted-by":"publisher","first-page":"611.e9","DOI":"10.1016\/j.cmi.2021.11.002","volume":"28","author":"F Bai","year":"2022","unstructured":"Bai, F. et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin. Microbiol. Infect. 28, 611.e9\u2013611.e16 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"57905_CR57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ijid.2020.10.099","volume":"102","author":"S Jang","year":"2021","unstructured":"Jang, S., Rhee, J.-Y., Wi, Y. M. & Jung, B. K. Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. Int. J. Infect. Dis. 102, 561\u2013565 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"57905_CR58","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm401712t","volume":"57","author":"YM Ba\u0301ez-Santos","year":"2014","unstructured":"Ba\u0301ez-Santos, Y. M. et al. X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases. J. Med. Chem. 57, 2393\u20132412 (2014).","journal-title":"J. Med. Chem."},{"key":"57905_CR59","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/gkm047","volume":"35","author":"NS Berrow","year":"2007","unstructured":"Berrow, N. S. et al. A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. Nucleic Acids Res. 35, e45 (2007).","journal-title":"Nucleic Acids Res."},{"key":"57905_CR60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.molcel.2016.06.015","volume":"63","author":"JN Pruneda","year":"2016","unstructured":"Pruneda, J. N. et al. The Molecular Basis for Ubiquitin and Ubiquitin-like Specificities in Bacterial Effector Proteases. Mol. Cell 63, 261\u2013276 (2016).","journal-title":"Mol. Cell"},{"key":"57905_CR61","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1107\/S1600577518003120","volume":"25","author":"D Arag\u00e3o","year":"2018","unstructured":"Arag\u00e3o, D. et al. MX2: a high\u2010flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian Synchrotron. J. Synchrotron Radiat. 25, 885\u2013891 (2018).","journal-title":"J. Synchrotron Radiat."},{"key":"57905_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"57905_CR63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1107\/S0907444905036693","volume":"62","author":"P Evans","year":"2006","unstructured":"Evans, P. Scaling and assessment of data quality. Acta Crystallogr. Sect. D: Biol. Crystallogr. 62, 72\u201382 (2006).","journal-title":"Acta Crystallogr. Sect. D: Biol. Crystallogr."},{"key":"57905_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1107\/S090744491003982X","volume":"67","author":"PR Evans","year":"2011","unstructured":"Evans, P. R. An introduction to data reduction: space\u2010group determination, scaling and intensity statistics. Acta Crystallogr. Sect. D 67, 282\u2013292 (2011).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"57905_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1107\/S2059798317016035","volume":"74","author":"L Potterton","year":"2018","unstructured":"Potterton, L. et al. CCP4i2: the new graphical user interface to the CCP4 program suite. Acta Crystallogr. Sect. D: Struct. Biol. 74, 68\u201384 (2018).","journal-title":"Acta Crystallogr. Sect. D: Struct. Biol."},{"key":"57905_CR66","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"57905_CR67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","volume":"55","author":"PD Adams","year":"2011","unstructured":"Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94\u2013106 (2011).","journal-title":"Methods"},{"key":"57905_CR68","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D: Biol. Crystallogr."},{"key":"57905_CR69","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1107\/S0907444909029436","volume":"65","author":"NW Moriarty","year":"2009","unstructured":"Moriarty, N. W., Grosse\u2010Kunstleve, R. W. & Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. Sect. D 65, 1074\u20131080 (2009).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"57905_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: More and better reference data for improved all\u2010atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."},{"key":"57905_CR71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"57905_CR72","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679\u2013682 (2022).","journal-title":"Nat. Methods"},{"key":"57905_CR73","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. -Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. -Aided Mol. Des."},{"key":"57905_CR74","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu, C. et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J. Chem. Theory Comput. 17, 4291\u20134300 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"57905_CR75","doi-asserted-by":"publisher","unstructured":"Bowers, K. J. et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. ACMIEEE SC 2006 Conf. (SC\u201906) 43\u201343 https:\/\/doi.org\/10.1109\/sc.2006.54 (2006).","DOI":"10.1109\/sc.2006.54"},{"key":"57905_CR76","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/prot.10613","volume":"55","author":"MP Jacobson","year":"2004","unstructured":"Jacobson, M. P. et al. A hierarchical approach to all\u2010atom protein loop prediction. Proteins: Struct., Funct., Bioinform. 55, 351\u2013367 (2004).","journal-title":"Proteins: Struct., Funct., Bioinform."},{"key":"57905_CR77","doi-asserted-by":"publisher","first-page":"W320","DOI":"10.1093\/nar\/gku316","volume":"42","author":"X Robert","year":"2014","unstructured":"Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320\u2013W324 (2014).","journal-title":"Nucleic Acids Res."},{"key":"57905_CR78","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1021\/ac9912247","volume":"72","author":"CD Bevan","year":"2000","unstructured":"Bevan, C. D. & Lloyd, R. S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72, 1781\u20131787 (2000).","journal-title":"Anal. Chem."},{"key":"57905_CR79","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1021\/jm0100990","volume":"44","author":"F Lombardo","year":"2001","unstructured":"Lombardo, F., Shalaeva, M. Y., Tupper, K. A. & Gao, F. ElogDo ct: a tool for lipophilicity determination in drug discovery. 2. basic and neutral compounds. J. Med. Chem. 44, 2490\u20132497 (2001).","journal-title":"J. Med. Chem."},{"key":"57905_CR80","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1124\/dmd.110.036988","volume":"39","author":"RE Curran","year":"2011","unstructured":"Curran, R. E. et al. Control and measurement of plasma ph in equilibrium dialysis: influence on drug plasma protein binding. Drug Metab. Dispos. 39, 551\u2013557 (2011).","journal-title":"Drug Metab. Dispos."},{"key":"57905_CR81","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1124\/dmd.32.6.647","volume":"32","author":"RL Walsky","year":"2004","unstructured":"Walsky, R. L. & Obach, R. S. Validated assays for human cytochrome p450 activities. Drug Metab. Dispos. 32, 647\u2013660 (2004).","journal-title":"Drug Metab. Dispos."},{"key":"57905_CR82","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1124\/dmd.106.012633","volume":"35","author":"RS Obach","year":"2007","unstructured":"Obach, R. S., Walsky, R. L. & Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35, 246\u2013255 (2007).","journal-title":"Drug Metab. Dispos."},{"key":"57905_CR83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/adt.2008.137","volume":"6","author":"DR Piper","year":"2008","unstructured":"Piper, D. R. et al. Development of the Predictor hERG Fluorescence Polarization Assay Using a Membrane Protein Enrichment Approach. ASSAY Drug Dev. Technol. 6, 213\u2013223 (2008).","journal-title":"ASSAY Drug Dev. Technol."},{"key":"57905_CR84","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5694\/mja2.50569","volume":"212","author":"L Caly","year":"2020","unstructured":"Caly, L. et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS\u2010CoV\u20102) from the first patient diagnosed with COVID\u201019 in Australia. Med. J. Aust. 212, 459\u2013462 (2020).","journal-title":"Med. J. Aust."},{"key":"57905_CR85","doi-asserted-by":"publisher","unstructured":"Hierholzer, J. C. & Killington, R. A. Virology Methods Manual. Sect. I: Class. Tech. 25\u201346 https:\/\/doi.org\/10.1016\/b978-012465330-6\/50003-8 (1996).","DOI":"10.1016\/b978-012465330-6\/50003-8"},{"key":"57905_CR86","doi-asserted-by":"publisher","first-page":"cpmc105","DOI":"10.1002\/cpmc.105","volume":"57","author":"EJ Mendoza","year":"2020","unstructured":"Mendoza, E. J., Manguiat, K., Wood, H. & Drebot, M. Two detailed plaque assay protocols for the quantification of infectious SARS\u2010CoV\u20102. Curr. Protoc. Microbiol. 57, cpmc105 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"57905_CR87","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jim.2015.04.012","volume":"421","author":"L Mielke","year":"2015","unstructured":"Mielke, L., Preaudet, A., Belz, G. & Putoczki, T. Confocal laser endomicroscopy to monitor the colonic mucosa of mice. J. Immunol. Methods 421, 81\u201388 (2015).","journal-title":"J. Immunol. Methods"},{"key":"57905_CR88","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bbi.2023.10.005","volume":"115","author":"EA Kleeman","year":"2024","unstructured":"Kleeman, E. A. et al. Paternal immune activation by Poly I:C modulates sperm noncoding RNA profiles and causes transgenerational changes in offspring behavior. Brain, Behav., Immun. 115, 258\u2013279 (2024).","journal-title":"Brain, Behav., Immun."},{"key":"57905_CR89","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1074\/mcp.M114.044305","volume":"14","author":"R Bruderer","year":"2015","unstructured":"Bruderer, R. et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues* [S]. Mol. Cell. Proteom. 14, 1400\u20131410 (2015).","journal-title":"Mol. Cell. Proteom."},{"key":"57905_CR90","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"57905_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/srep40292","volume":"7","author":"JR Clasman","year":"2017","unstructured":"Clasman, J. R. et al. X-ray Structure and Enzymatic Activity Profile of a Core Papain-like Protease of MERS Coronavirus with utility for structure-based drug design. Sci. Rep. 7, 40292 (2017).","journal-title":"Sci. Rep."},{"key":"57905_CR92","unstructured":"Calleja, D. https:\/\/BioRender.com\/x19l912 (2025)."},{"key":"57905_CR93","unstructured":"M. Bader, S. https:\/\/BioRender.com\/l61i909 (2025)."},{"key":"57905_CR94","unstructured":"M. Bader, S. https:\/\/BioRender.com\/k84n296 (2025)."},{"key":"57905_CR95","unstructured":"M. Bader, S. https:\/\/BioRender.com\/y55n931 (2025)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57905-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:08:12Z","timestamp":1743786492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57905-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["57905"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-57905-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work is protected under provisional patent AU2024900559. The authors declare the following competing interests; D.K. is founder, shareholder and SAB member of Entact Bio and Proxima Bio. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2900"}}